P044: First report of GLP-1 agonist use in MCAD deficiency

Genetics in Medicine Open 2026 Open access

Read full text
Authors: Shaindy Grunwald, Amy Taylor, Kristen Stackpole, Ben Cocanougher, Olivia D'Annibale
DOI: 10.1016/j.gimo.2026.103535
Cited by: 0

Abstract

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an autosomal recessive disorder of mitochondrial fatty acid oxidation. Affected individuals lack functional MCAD enzyme and are unable to metabolize medium-chain fatty acids, which can lead to metabolic crises and decompensation during periods of fasting. Standard management includes avoidance of fasting, caloric restriction, and high-fat/low-carbohydrate diets. Weight loss strategies that involve caloric restriction are typically contraindicated.

Fields of Study & Subjects

Metabolism and Genetic Disorders Diet and metabolism studies Lipid metabolism and disorders

Publication details

Journal / source
Genetics in Medicine Open
Volume
4
Pages
103535–103535
Publication date
1 January 2026
Language
EN